Oral semaglutide does not slow the progression of Alzheimer's disease, according to a trial Oral semaglutide is not effective in slowing the progression of the disease in patients with mild Alzheimers disease, according to the findings of the first large-scale, randomised phase 3 clinical trials published in The Lancet
What makes functional medicine different is how we interpret those results, connect them to your symptoms, and build a treatment plan around the whole story, not just numbers on a page
***Behavioral Safety*** During treatment, BRP did not induce anxiety-like behaviors, changes in locomotor activity, water intake, or sucrose preference in mice
Serious but rare adverse effects include pancreatitis, gallbladder disease, acute kidney injury (particularly with severe dehydration from vomiting or diarrhoea), and potential thyroid effects